AntibodySystem continues to upgrade product qualities and lower the overall cost, offering accountable and affordable solutions for biolabs all over the world. Since its establishment, AntibodySystem has built long term and stable collaborations with academia, pharmaceutical industry, biotech companies and ...
Bezlotoxumab cost effective for Clostridium difficile infectiondoi:10.1007/s40274-017-4529-zSpringer International PublishingPharmacoeconomics & Outcomes News
Even though the acquisition costs of bezlotoxumab are even higher than for fidaxomicin, Markov modelling—with its inherent limitations—indicates that bezlotoxumab might be cost-effective [175,188,189]. Of note, two of these studies were financially supported by the manufacturer of bezlotoxumab...
Cost of bezlotoxumab vial is 鈧 1,480. Estimated expenditure was: 鈧 51,800 if patients were cited vs 鈧 66,600 if not. The cost of treatment decreased by 鈧 14,800 due to the administration appointment strategy. Conclusion and Relevance Bezlotoxumab is an effective treatment in ...
Bezlotoxumab plus vancomycin led to a QALY gain of 11.77 at an incremental cost of $17 746 per QALY. At the willingness-to-pay (WTP) threshold of $150 000 per QALY, extended-pulsed fidaxomicin, bezlotoxumab plus vancomycin and standard fidaxomicin were more cost-effective compared with ...
bezlotoxumabcost-effectivenessMarkov modelBackground. Clostridium difficile infection (CDI) is the most commonly recognized cause of recurrent diarrhea. Bezlotoxumab, administered concurrently with antibiotics directed against C. difficile (standard of care [SoC]), has been shown to reduce the ...
Although cost remains an important factor against its widespread use, simpler administration, fewer side-effects, and better social acceptability justify its consideration for treating rCDI.doi:10.1080/14712598.2017.1363886Expert Opinion on Biological Therapy...
Due to its high cost, it is used in a population and under conditions slightly different to those referred to in the MODIFY clinical trials. Due to the scarcity of real-life studies, it is necessary to collect data on the effectiveness of bezlotoxumab in daily hospital practice.Aim and ...
PIN11 COST-EFFECTIVENESS OF BEZLOTOXUMAB AND FIDAXOMICIN FOR RECURRENT C. DIFFICILE INFECTIONdoi:10.1016/j.jval.2020.04.487J. ChenC. GongM.M. HitchcockM. HolubarJ.W. HayValue in Health